Quantum-Si IncQSI

Quantum-Si Inc reported first-quarter revenue of $258,000 for the three months to 31 March 2026, a figure that would barely cover the lab consumables for a single proteomics run at a mid-tier university. Net loss attributable to parent widened to $21.7m, while operating cash burn totalled $25.6m, leaving the company to fund its ambitions with a cash pile of $36.2m. Diluted loss per share was ten cents against 216.5m shares outstanding, numbers that look less like a growth story and more like a cost-of-living crisis in the C-suite. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1816431/000181643126000040/0001816431-26-000065-index.htm)

Quantum-Si describes itself as a provider of next-generation protein sequencing platforms built on semiconductor, photonics and microfluidics, aiming to push single-molecule sensitivity into the clinical workflow. The technology is real and the ambition is large: replace legacy mass-spectrometry and optical-readout workflows with a silicon-based cartridge that sequences proteins at scale. The filing does not, however, disclose customer counts, repeat-order rates, or any evidence that the platform has graduated from prototype to revenue-generating installed base. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1816431)

The 10-Q shows research and development expense of $14.5m in the quarter, capitalised software development costs of $279k, and inventory of $2.2m, up $278k from the prior quarter. Total assets stood at $213.3m versus liabilities of $12.6m, giving shareholders an equity cushion of $200.7m. Yet the company generated no free cash flow and its operating cash burn accelerated to $25.6m, a pace that would exhaust the current cash balance in roughly fourteen months if it continues unchecked. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1816431/000181643126000040/0001816431-26-000065-index.htm)

Insiders filed four Form 4 disclosures on 24 June 2026 detailing mandatory sell-to-cover transactions to cover tax withholding on vested restricted stock units, a reminder that the company’s equity compensation arrangements are now the primary mechanism converting paper gains into real cash outflows. The 8-K published on 24 July 2026 confirms the vesting of restricted stock units on 20 June 2026, reinforcing the optics of a board that prefers to reward executives with shares even as the cash register sings a different tune. The 144 filing for the same date lists the restricted stock unit vesting programme, underscoring the structural tilt toward dilution over buybacks. (source: SEC EDGAR, URLs: https://www.sec.gov/Archives/edgar/data/1816431/000114036126026294/xslF345X06/form4.xml, https://www.sec.gov/Archives/edgar/data/1816431/000185691226000002/xsl144X01/primary_doc.xml)

From a charting perspective, Quantum-Si’s equity trades on the Nasdaq Capital Market under the symbol QSI. The stock has no meaningful volume or price history in the evidence pack, so any reference to price action, support, resistance, or sentiment would be pure projection rather than sourced fact. The company’s market capitalisation is therefore unknowable from the filings provided, and any claim about valuation bands would lack evidentiary grounding. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1816431)

What Quantum-Si does next hinges on whether its next-generation protein sequencing platform can convert pilot installations into repeat orders, and whether the board can pivot from share-based compensation to cash discipline before the runway shortens. The filing set does not contain customer concentration data, order backlog, or any signed contracts beyond the $258k recorded in the quarter. Until revenue scales materially and cash burn slows, the story remains a platform narrative in search of a balance sheet. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1816431/000181643126000040/0001816431-26-000065-index.htm)

The most immediate evidence that would change the file would be a follow-on 10-Q or 8-K disclosing signed customer agreements, installed base growth, or a concrete cash-raising event. Absent those, the company’s equity story is a bet on a technology that has yet to prove it can outrun its own burn rate. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1816431)